The discovery of a new BCL-2 inhibitor offers fresh hope in the fight against cancer, harnessing the body's own death machinery to destroy tumor cells.
Exploring how molecular architects design hybrid compounds and metal complexes to create more effective, targeted cancer treatments with reduced side effects.
Discover how scientists used spectroscopy and molecular modeling to understand the interaction between lung cancer drug Olmutinib and blood protein AGP.
Exploring the potential of spiro-chromeno-thiazole derivatives as next-generation cancer therapeutics with dual-targeting capabilities